| 摘要: |
| ［摘要］ 肾细胞癌(renal cell carcinoma，RCC)是泌尿外科中位居第二的恶性肿瘤，晚期RCC的治疗方法有限，放疗和化疗均不敏感。最近开展的靶向治疗为RCC患者带来了福音。肿瘤的靶向治疗的作用机理主要是抑制肿瘤血管形成和肿瘤细胞增殖。肿瘤血管形成受多种因素的影响，受如血管内皮生长因子（vascular endothelial growth factor，VEGF)等多种因子调节。促血管生成素-2（Angiopoietin-2，Ang-2）已被表明是血管形成的一个关键因子。有临床研究证明，通过阻断VEGF来治疗RCC已经成为一种有效方法。Ang-2和VEGF在调节血管形成的过程中呈协同作用。随着对Ang-2、VEGF的深入研究发现，Ang-2不仅可能作为靶点运用于RCC治疗，而且可能联合VEGF应用于RCC的治疗。该文就Ang-2和VEGF在RCC治疗中作用的研究概况作一综述。 |
| 关键词: 肾细胞癌 促血管生成素-2 血管内皮生长因子 治疗 |
| DOI：10.3969/j.issn.1674-3806.2017.05.31 |
| 分类号:R 737 |
| 基金项目:山西省自然科学基金（编号：2014011038-3） |
|
| Research progress of Ang-2 and VEGF in treatment of renal cell carcinoma |
|
WANG Jie, HAN Hui, QIN Zhen-zhen, et al
|
|
Shanxi Medical University, Taiyuan 030001, China
|
| Abstract: |
| ［Abstract］ Renal cell carcinoma(RCC) is the second malignant tumors in the department of urology. The treatment of advanced RCC is limited, because it is not sensitive to radiotherapy and chemotherapy. Recently, targeted therapy has brought hope for the patients with RCC. Tumor targeted therapy mainly inhibits tumor angiogenesis and tumor cell proliferation. Tumor angiogenesis is influenced by many factors, and is regulated by many factors, like vascular endothelial growth factor(VEGF). Angiopoietin-2(Ang-2) has been shown to be a key regulator factor of angiogenesis. Clinical studies have confirmed that blocking VEGF has become an effective way to treat RCC. VEGF and Ang-2 have a synergistic effect on the regulation of angiogenesis. With the developments of these studies, Ang-2 can not only be used as a target for RCC treatment, but also be combined with VEGF in the treatment of RCC. The research progress of Ang-2 and VEGF in the treatment of RCC is reviewed in this paper. |
| Key words: Renal cell carcinoma Angiopoietin-2 Vascular endothelial growth factor Treatment |
